$195.800
+1.723 (+0.88%)At close
DOV News
DOV Events
Dover Launches Intelligent Pharmaceutical Traceability Platform Systech TraceIQ
Dover's Systech announced the launch of Systech TraceIQ, an intelligent enterprise traceability platform created for a new operational reality in pharmaceutical supply chains. TraceIQ combines core compliance capabilities with an operational intelligence layer enhanced by AI-assisted analytics designed for pharmaceutical supply chains. TraceIQ transforms traceability data from a passive record of transactions into an active source of insight.
Dover Corporation Increases Quarterly Cash Dividend to 52.5 Cents
The Board of Directors of Dover Corporation increased its quarterly cash dividend to 52.5c per share, from the previous 52c per share, an increase of 0.5c. This is the 71st consecutive year in which the company has increased its annual cash dividend, demonstrating Dover's longstanding commitment to returning capital to shareholders.
Dover Signs Agreement to Acquire Cloeren
Dover announced that it has signed a definitive agreement to acquire Cloeren. Cloeren will become part of the MAAG business unit within Dover's Pumps & Process Solutions segment following the closing of the deal. The company is based in Orange, Texas, near North America's petrochemical and energy export hub, with additional manufacturing locations in Marshall, Texas; Eau Claire, Wisconsin and Micheldorf, Austria. The transaction is expected to close in the third quarter following satisfactory completion of customary closing conditions. The terms of the transaction were not disclosed.
Dover Reports Q2 Revenue of $2.19B, Slightly Below Consensus
Reports Q2 revenue $2.19B, consensus $2.2B. Dover's President and Chief Executive Officer, Richard J. Tobin, said, "Dover delivered another strong quarter of double-digit earnings per share growth. Top-line performance was led by our secular-growth-exposed markets - which now account for approximately 25% of the total portfolio - and was complemented by broad-based, constructive trading conditions across the portfolio. Notably, all five segments delivered positive organic growth in the quarter, underscoring the breadth and durability of demand. Margin performance was solid, as continued operational execution on incremental volumes more than offset input cost inflation."
Company Raises FY26 Revenue Outlook to 6%-8% Growth
Consensus $10.64. Raises FY26 revenue view to up 6%-8% from up 5%-7%. The company said, "As we look to the back half of the year, we are well positioned to drive continued value creation for our shareholders. The underlying strength of our order book, together with the flexibility of our business model and the optionality of our balance sheet, afford us the ability to respond dynamically to market conditions and quickly capitalize on opportunities as they arise. Accordingly, we are raising our full-year adjusted EPS guidance."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.